Given the potential for viral resistance, DAAs are often used in combination therapies. For instance, in treating HCV, a regimen may include multiple DAAs targeting different viral proteins. This multi-target approach reduces the likelihood of resistance and enhances overall efficacy. Combination therapies are also standard in treating HIV, where different drugs target various stages of the viral life cycle.
